Tempus AI Inc. announced a collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly into Flatiron’s cloud-based Electronic Medical Record platform, OncoEMR, through the Molecular Profiling Integration.
Personalis Inc. announced the commencement of commercialization efforts by Tempus for NeXT Personal, Personalis’ ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease and recurrence in cancer.
